Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lower limbs in women. A debated issue is if-and to what extent-melanoma development can be attributed to gender-specific behaviors or to biologically intrinsic differences. In the search for factors responsible for the divergences, a pivotal role of sex hormones has been observed, although conflicting results indicate the involvement of other mechanisms. The presence on the X chromosome of numerous miRNAs and coding genes playing immunological roles represents another important factor, whose relevance can be even increased by the incomplete X chromosome random inactivation. Considering the known advantages of the female immune system, a different cancer immune surveillance efficacy was suggested to explain some sex disparities. Indeed, the complexity of this picture emerged when the recently developed immunotherapies unexpectedly showed better improvements in men than in women. Altogether, these data support the necessity of further studies, which consider enrolling a balanced number of men and women in clinical trials to better understand the differences and obtain actual gender-equitable healthcare.

Sex and gender disparities in melanoma / Bellenghi, Maria; Puglisi, Rossella; Pontecorvi, Giada; De Feo, Alessandra; Carè, Alessandra; Mattia, Gianfranco. - In: CANCERS. - ISSN 2072-6694. - 12:7(2020), pp. 1-24. [10.3390/cancers12071819]

Sex and gender disparities in melanoma

Maria Bellenghi
Co-primo
;
Rossella Puglisi
Co-primo
;
Giada Pontecorvi
Secondo
;
Alessandra De Feo;
2020

Abstract

Worldwide, the total incidence of cutaneous melanoma is higher in men than in women, with some differences related to ethnicity and age and, above all, sex and gender. Differences exist in respect to the anatomic localization of melanoma, in that it is more frequent on the trunk in men and on the lower limbs in women. A debated issue is if-and to what extent-melanoma development can be attributed to gender-specific behaviors or to biologically intrinsic differences. In the search for factors responsible for the divergences, a pivotal role of sex hormones has been observed, although conflicting results indicate the involvement of other mechanisms. The presence on the X chromosome of numerous miRNAs and coding genes playing immunological roles represents another important factor, whose relevance can be even increased by the incomplete X chromosome random inactivation. Considering the known advantages of the female immune system, a different cancer immune surveillance efficacy was suggested to explain some sex disparities. Indeed, the complexity of this picture emerged when the recently developed immunotherapies unexpectedly showed better improvements in men than in women. Altogether, these data support the necessity of further studies, which consider enrolling a balanced number of men and women in clinical trials to better understand the differences and obtain actual gender-equitable healthcare.
2020
immunity; immunotherapy; melanoma; microRNAs; sex-hormones; sex/gender
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Sex and gender disparities in melanoma / Bellenghi, Maria; Puglisi, Rossella; Pontecorvi, Giada; De Feo, Alessandra; Carè, Alessandra; Mattia, Gianfranco. - In: CANCERS. - ISSN 2072-6694. - 12:7(2020), pp. 1-24. [10.3390/cancers12071819]
File allegati a questo prodotto
File Dimensione Formato  
Bellenghi_Sex_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.72 MB
Formato Adobe PDF
1.72 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1433804
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 59
social impact